< Previous30FINAL PROGRAMME – 31st ECCMID Online 2021 Scientific Programme Friday, 9 July 2021 2648 08:30 - 10:00 1. Viral infections 1,5-hour Symposium Hot topics in HIV infection Chairs Andrew Kambugu (Kampala, Uganda) Karine Lacombe (Paris, France) 2648-1 08:30 HIV, weight gain and metabolic disorders Giovanni Guaraldi (Modena, Italy) 2648-2 08:50 HIV and COVID-19 co-infection Laura Waters (London, United Kingdom) 2648-3 09:10 Therapeutic strategies in HIV Alexandra Calmy (Geneva, Switzerland) 2648-4 09:30 Acute HIV infection and HIV cure Sarah Fidler (London, United Kingdom) 09:50 Q&A/Discussion S26 08:30 - 09:30 2. Bacterial infection 1-hour Oral Case Session Updates from patients with bacterial infection from the time of COVID-19 to the time of the Black Death Chair Aisha Abubakar (Zaria, Nigeria) 2479 08:30 Description of an outbreak of Legionella pneumophila pneumonia in an urban setting in Northern Italy during the COVID-19 pandemic J. Testa* (Busto Arsizio, Italy), S. Tunesi, M. Farinazzo, D. Zola, C. Abeli, G. Chieffo, B. Menzaghi, M.G. Pizzi, D. Radrizzani, P. Vitiello, C.G. Zeroli, F. Franzetti 333 08:40 Vascular infections, there may be more than what meets the eye: the hidden chronic Q fever M. Puges* (Bordeaux, France), X. Bérard, C. Caradu, M. Ducours, C. Eldin, N. Sauvage, M.O. Vareil, L. Alleman, F. Mzali, M. Carrer, S. Pereyre, C. Cazanave 518 08:50 Post CAR-T cell therapy STD, make sure you know how to consult your patients M. Dekel* (Tel Aviv, Israel), R. Cohen-Poradosu 2974 09:00 Clostridial prosthetic joint infections: a series of 16 cases A.G. Leroy* (Nantes, France), L. Manceau, P. Bémer, J. Decroo, P. Le Turnier, V. Crenn, A. Jolivet-Gougeon, C. Plouzeau-Jayle, M.F. Lartigue, L. Bouard, R. Chenouard, C. Mazuet, S. Corvec 278 09:10 First genetic evidence of the plague in the abbey of San Leonardo (Apulia, Italy): tracing the cause of death in two individuals buried with coins D.A. Raele* (Foggia, Italy), G. Panzarino, G. Sarcinelli, M.A. Cafiero, A.M. Tunzi, E. Dellù 09:20 Q&A/Discussion ID ID 2166 08:30 - 11:00 3. Antimicrobial resistance 2,5-hour Educational Workshop Antimicrobial susceptibility testing with EUCAST methods and breakpoints Chairs Petra Apfalter (Linz, Austria) Waleria Hryniewicz (Warsaw, Poland) 2166-1 08:30 EUCAST Update Christian Giske (Stockholm, Sweden) 2166-2 08:45 Susceptible – Increased exposure and Area of Technical Uncertainty: the story so far Gunnar Kahlmeter (Växjö, Sweden) 2166-3 09:00 Aminoglycosides revisited Shampa Das (Liverpool, United Kingdom) 2166-4 09:15 Piperacillin-tazobactam breakpoints in the wake of the Merino trial Alasdair Macgowan (Bristol, United Kingdom) 2166-5 09:30 Breakpoints for meningitis Christoffer Lindemann (Bergen, Norway) 2166-6 09:45 Advances in mycobacterial AST Emmanuelle Cambau (Paris, France) 2166-7 10:00 Antifungal susceptibility testing: update Maiken Cavling Arendrup (Copenhagen, Denmark) 2166-8 10:15 AST of Stenotrophomonas and Burkholderia Mandy Wootton (Cardiff, United Kingdom) 10:30 Q&A/Discussion Co-organised with: European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee 2645 08:30 - 09:30 4. Diagnostics Meet-the-Expert Session Multiplexed diagnostic panels: benefits, pitfalls and clinical applicability 2645-1 Massimo Girardis (Modena, Italy) 2645-2 Maria Angeles Dominguez Luzon (L'Hospitalet de Llobregat, Spain) Co-organised with: Portuguese Society of Infectious Diseases and Clinical Microbiology S30 08:30 - 09:00 5. Antimicrobials & stewardship 30min ePoster Review Antimicrobial stewardship in children Moderator Vana Spoulou (Nea Erythraia, Greece) 1246 Population pharmacokinetic model-informed dosing of vancomycin in neonates E. Chung* (Toronto, Canada), W. Seto CM CMScientific Programme 31FINAL PROGRAMME – 31st ECCMID Online 2021 2012 Global antibiotic dosing strategies in hospitalised children and impact on guidelines M. Sharland* (London, United Kingdom), M. Clements, N. Russell, J. Bielicki, S. Ellis, S. Gastine, Y. Hsia, J. Standing, S. Walker 2160 Effectiveness of a new antibiotic stewardship programme amongst paediatric patients in a tertiary hospital in Vietnam H.Q. Nguyen* (Ho Chi Minh City, Vietnam), D.T.N. Le, P.T. Huynh, Y. Hsia 2258 Staphylococcal bacteraemia in neonates: microbiology results and opportunities for improved antibiotic stewardship A.M. Al-Hamad* (Inak, Saudi Arabia), S.M. Rahman, M.M. Al-Ibrahim, J.A. Altowaileb, R.A. Gazewi, F.M. Alhamad, G.A. Alzaher 3044 Global estimates of the relative paediatric consumption and cost of oral amoxicillin and amoxicillin-clavulanic acid G. Levine* (Basel, Switzerland) 3247 Rapid progression around the antibiotic wheel: analysis of a multi-country prospective neonatal observational study (NeoOBS) N. Russell* (Exeter, United Kingdom), E. Iosifidis, E. Roilides, O.B.O. The Neoobs Study Group 3303 Pilot pharmacokinetic study with intravascular microdialysis catheters modified for paediatric use V. Al Jalali* (Vienna, Austria), B. Wulkersdorfer, P. Matzneller, S. Poschner, W. Jäger, M. Zeitlinger 865 Population pharmacokinetic modelling for ceftaroline in plasma in paediatric and adult subjects including patients with cystic fibrosis (CF) P.L. Chan* (Sandwich, United Kingdom), L. Mcfadyen, V.M. Hendrick, J. Le, J.S. Bradley, E.B. Autry, E.E. Barsky, A. Quaye, S. Raber All ePosters will be reviewed by the moderator. 2183 08:30 - 09:30 6. Fungal infections 1-hour Symposium Improving the impact of fungal diagnostic tests on patient management Chairs Sevtap Arikan-Akdagli (Ankara, Turkey) Thomas Rogers (Dublin, Ireland) 2183-1 08:30 Conventional tests and biomarkers: which combination for which patient groups? Cornelia Lass-Flörl (Innsbruck, Austria) 2183-2 08:50 Integration of fungal diagnostic tests in care pathways Malgorzata Mikulska (Genoa, Italy) 09:10 Q&A/Discussion Co-organised with: ESCMID Fungal Infection Study Group (EFISG) CM S24 08:30 - 09:30 7. Parasites & international health 1-hour Oral Session Malaria: diagnosis and resistance Chairs Hans-Peter Fuehrer (Vienna, Austria) Johannes Mischlinger (Hamburg, Germany) 849 08:30 Identification and characterisation of Plasmodium falciparum parasites undetected by histidine-rich protein (HRP) antigen tests in imported malaria A. Gray* (London, United Kingdom), D. Nolder, L. Stewart, J. Tucker, T. Corrah, C. Gallagher, L. John, E. O’brien, D. Aggarwal, E. Benavente, D. Van Schalkwyk, G. Henriques, N. Sepulveda, S. Campino, P. Chiodini, C. Sutherland, K. Beshir 2389 08:40 Selective whole genome amplification from imported Plasmodium ovale spp. clinical samples V. Joste* (Paris, France), R. Coppée, E. Guillochon, J. Clain, S. Houzé 2999 08:50 Loop-mediated isothermal amplification for the diagnosis of imported malaria in Milan, Italy: a retrospective observational study A. Giacomelli* (Milan, Italy), M.E. Monti, R. Grande, L. Oreni, L. Galimberti, A.L. Ridolfo, C. Bonazzetti, F. Sabaini, L. Cordier, A. Zambelli, G. Rizzardini, M. Galli, S. Antinori 4225 09:00 Emergence and expansion of piperaquine resistance in French Guiana over a period of 20 years C. Florimond* (Cayenne, French Guiana), F. De Laval, Y. Lazrek, S. Pelleau, S. Sauthier, F. Morin, N. Taudon, L. Musset 09:10 Q&A/Discussion S82 08:30 - 09:30 8. Infection prevention & control 1-hour Oral Session Reducing the burden of transmissions Chairs Monica Junie (Cluj-Napoca, Romania) Axel Kola (Berlin, Germany) 4192 08:30 Impact of active surveillance on Clostridioides difficile infection transmission: 14 years of experience in a large university hospital N. Khanafer* (Lyon, France), C. Services, L. Oltra, V. Pergay, O. Dauwalder, F. Vandenesch, P. Vanhems 1297 08:40 Failing methicillin-resistant Staphylococcus aureus decolonisation, is the carrier or the bacterial strain responsible? M.K.A. Holm* (Lyngby, Denmark), K.M. Jørgensen, K. Bagge, P. Worning, M. Pedersen, H. Westh, J.M. Monk, M.D. Bartels CM IC Friday, 9 July 202132FINAL PROGRAMME – 31st ECCMID Online 2021 3640 08:50 Modelling the cost-effectiveness of control strategies for carbapenemase-producing Enterobacteriaceae L. Kardas-Sloma* (Paris, France), I. Durand- Zaleski, J.C. Dupont, L. Rochaix, S. Fournier, F.X. Lescure, J.R. Zahar, S. Kernéis, J.C. Lucet 1373 09:00 Dynamics of methicillin-sensitive Staphylococcus aureus in patients and the environment A.S. Van Der Schoor* (Rotterdam, Netherlands), A.F. Voor In ‘t Holt, C.H.W. Klaassen, D. Gommers, M.J. Bruno, J.M. Hendriks, J.A. Severin, M.C. Vos 2786 09:10 Shining a light on the impact of ultraviolet (UV) technology in the reduction of environmentally implicated infections K.S. Kaye* (Ann Arbor, United States), P. Kilgore, P. Carling, T. Chopra, E. Todter, G. Divine, C. Jinadatha, S. Dhar 09:20 Q&A/Discussion S8 08:30 - 09:30 10. Immunology & vaccinology 1-hour Mini Oral Flash Advances in understanding immune responses to important human pathogens Chairs Tessa Andermann (Chapel Hill, United States) Trine Rolighed Thomsen (Aarhus, Denmark) 5 08:30 Klebsiella pneumoniae lipopolysaccharides serotype O2afg induce poor inflammatory immune responses ex vivo B. Douradinha* (Palermo, Italy), M. Bulati, R. Busà, C. Carcione, G. Iannolo, G. Di Mento, N. Cuscino, A.P. Carreca, F. Barbera, F. Monaco, F. Cardinale, P.G. Conaldi 1713 08:35 WOLF: a liquid handling device to facilitate whole blood cell-mediated immunity testing A. Garritsen* (Oss, Netherlands), A. Scholzen, W. Teunissen, F. Van Oudheusden, M. Kouwijzer, R. Kneusel, H. Stockinger, H. Van Der Vegt 2428 08:40 Longitudinal Mycobacterium tuberculosis specific interferon- γ responses in Ethiopian HIV-negative women during pregnancy and post-partum F. Tesfaye* (Adama, Ethiopia), J. Walles, E. Sturegård, N. Winqvist, T.T. Balcha, M. Kefeni, M. Jansson, P. Björkman 2717 08:45 Immunological and clinical assessment of patients with Lyme neuroborreliosis identifies a unique immune and genetic signature in Bannwarth syndrome K. Strle* (Albany, United States), K. Ogrinc, S. Hernandez, M. Korva, P. Bogovic 3680 08:50 Decreased IL-1 β secretion is associated with the risk of tuberculosis recurrence in individuals diagnosed with HIV M. Nosik* (Moscow, Russian Federation), K. Ryzhov, U. Kuimova, A. Kravtchenko, A. Sobkin ID 3463 08:55 Higher expression of PD-1 on CD4 + T cells in pulmonary tuberculosis: implication in cavitary and non-cavitary lesions S. Halkur Shankar* (New Delhi, India), P. Kaur, D.K. Mitra, A. Ray, K. Madan, M. Soneja, R.M. Pandey, A. Biswas 3272 09:00 Interferon responses in patients with varying severity of acute dengue infection S. Dayarathna* (Nugegoda, Sri Lanka), K.C. Jeewandara, V. Vimalahan, G.S. Ogg, G.N. Malavige 2130 09:05 Pharmacokinetics of radiolabeled anti-mouse PD-L1 in immune-challenged tumour-bearing mice E. Aarntzen* (Nijmegen, Netherlands), G. Sandker, P. Wierstra, J. Molkenboer-Kuenen, M. Gotthardt, G. Adema, J. Bussink, S. Heskamp 09:10 Q&A/Discussion S56 08:30 - 09:30 12. COVID-19 1-hour Oral Session COVID-19 and thromboembolic disease Chairs Jeremy Day (Ho Chi Minh City, Vietnam) Pontus Naucler (Åkersberga, Sweden) 3161 08:30 Thrombosis pathways in COVID-19 versus influenza-associated acute respiratory distress syndrome (ARDS): a targeted proteomics approach E. Rademaker* (Utrecht, Netherlands), N. Kusadasi, J. Drylewicz, A. Huisman, I. Hofer, M. Bonten, C. Maas, S. Rooijakkers, L. Derde, O. Cremer 2857 08:40 Venous thromboembolic disease and D-dimer in non-critically ill patients with COVID-19 pneumonia J. Sellarès-Nadal* (Barcelona, Spain), G. Casas, D. Gil-Sala, J. Andreu-Soriano, J. Navarro, V. Falcó, J.M. Suriñach, P. Bosch-Nicolau 989 08:50 Increased incidence of secondary infections in COVID-19 patients with thrombotic complications M. Ripa* (Milan, Italy), L. Galli, A. d’Angelo, L. Apruzzi, D. Palumbo, C. Campochiaro, C. Tassan Din, A. Danise, V. Da Prat, G. Vitali, L. Brugliera, A. Poli, G. Landoni, D. Baccellieri, F. De Cobelli, M. Clementi, S. Iannaccone, L. Dagna, P. Rovere Querini, F. Ciceri, M. Tresoldi, A. Zangrillo, P. Scarpellini, A. Castagna ID Friday, 9 July 2021Scientific Programme 33FINAL PROGRAMME – 31st ECCMID Online 2021 1038 09:00 Early treatment with low-molecular-weight heparin reduces mortality rate of SARS- CoV-2 patients A. De Vito* (Sassari, Italy), L. Saderi, V. Fiore, N. Geremia, E. Princic, A.A. Muredda, C. Fanelli, I. Maida, C.M. Panu Napodano, E. Bogliolo, G. Moi, A.G. Fois, G. Sotgiu, G. Madeddu, S. Babudieri 09:10 Q&A/Discussion 2619 09:00 - 10:30 11. Special sessions & Other 1,5-hour Educational Workshop Medical guidelines development during and after the pandemic Chairs Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom) Amel Letaief (Sousse, Tunisia) 2619-1 09:00 PICO questions Sarah Tschudin Sutter (Basel, Switzerland) 2619-2 09:20 Evidence review and SOF table Luigia Scudeller (Bologna, Italy) 2619-3 09:40 Evidence to recommendation Mical Paul (Haifa, Israel) 10:00 Q&A/Discussion Co-organised with: ESCMID Guideline Subcommittee 2620 09:30 - 10:30 2. Bacterial infection Meet-the-Expert Session Guidelines on Nontuberculous mycobacterial pulmonary disease 2620-1 Claire Andrejak (Amiens, France) 2620-2 Jakko Van Ingen (Nijmegen, Netherlands) Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC) 2205 09:30 - 10:30 4. Diagnostics Meet-the-Expert Session How to implement NGS into routine clinical diagnostics and microbial typing? 2205-1 Sandra Reuter (Freiburg, Germany) 2205-2 Adrian Egli (Basel, Switzerland) Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD) PH ID CM S11 09:30 - 10:30 5. Antimicrobials & stewardship 1-hour Mini Oral Flash Innovative PK/PD approaches to improve dosing Chairs Elena Carrara (Verona, Italy) Paul M. Tulkens (Brussels, Belgium) 3338 09:30 Imipenem population pharmacokinetics in neutropaenic adults patients M. Lafaurie* (Paris, France), K. Hammas, A. Goldwirt, H. Sauvageon, P. Houzé, B. Bercot, A.M. Fourmont, F. Mentre, J.M. Molina, C. Burdet 3863 09:35 Model-informed translation of in vitro meropenem effects against Pseudomonas aeruginosa to diverse clinical situations I.K. Minichmayr* (Uppsala, Sweden), L.E. Friberg 387 09:40 Characterisation of nacubactam pharmacokinetics-pharmacodynamics (PK-PD) for efficacy in combination with cefepime against carbapenemase-producing Enterobacterales in a one compartment in vitro infection model B.D. Vanscoy* (Schenectady, United States), A. Mullarkey, H. Conde, A. Caranco, C.M. Rubino, S.M. Bhavnani, Y. Nagira, K. Asai, K. Kondo, P.G. Ambrose 3411 09:45 Pharmacokinetics of nebulised and intravenous colistin in mechanically ventilated patients M. Bhatt* (New Delhi, India), M. Soneja, U. Subash Das, T. Velpandian, H. Gautam, A. Kapil, N. Wig 1412 09:50 Population pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers A.E. Edwina* (Rotterdam, Netherlands), B. Koch, V. Al Jalali, P. Matzneller, M. Zeitlinger, S. Sassen 3607 09:55 Population pharmacokinetics of cefazolin in maternal and umbilical cord sera and target attainment in term neonates O. Elkayal* (Leuven, Belgium), K. Allegaert, I. Spriet, A. Smits, M.C. Seghaye, C. Charlier, E. Dreesen 3352 10:00 Probability of target attainment of antibiotics in obese patients can conventional pharmacokinetic/pharmacodynamic targets adequately capture target-site penetration? D. Busse* (Berlin, Germany), P. Simon, N. Hartung, L. Schmitt, D. Petroff, C. Dorn, R. Michelet, H. Wrigge, C. Kloft 1983 10:05 Amikacin in emergency surgery: how to dose it optimally? S. Goutelle* (Lyon, France), G. Fritsch, M. Leroy, C. Piron, C. Salvez, A. Friggeri 981 10:10 A semi-mechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis K. Gausi* (Cape Town, South Africa), E. Ignatius, X. Sun, S. Kim, L. Moran, L. Wiesner, F. Von Groote-Bidlingmaier, R. Hafner, K. Donahue, N. Vanker, S.L. Rosenkranz, S. Swindells, A.H. Diacon, E.L. Nuermberger, K.E. Dooley, P. Denti ID Friday, 9 July 202134FINAL PROGRAMME – 31st ECCMID Online 2021 646 10:15 Influence of the clindamycin-administration route on the magnitude of clindamycin– rifampicin interaction: a prospective pharmacokinetic study V. Zeller* (Paris, France), S. Magreault, B. Heym, D. Salmon, M.D. Kitzis, E. Billaud, S. Marmor, A.S. Jannot, L. Salomon, V. Jullien 10:20 Q&A/Discussion S222 09:30 - 10:30 6. Fungal infections 1-hour ePoster Review Mycology from bench to bedside Moderators Felix Bongomin (Gulu, Uganda) Michaela Lackner (Innsbruck, Austria) 1017 Breakthrough invasive fungal infections in high-risk oncohaematological patients with different primary antifungal prophylaxis strategies A.N. Rearte* (Buenos Aires, Argentina), F. Herrera, F. Bues, R. Rojas, D. Torres, E. Temporiti, S. Relloso, A. Carena, F. Poletta, P. Bonvehí 1070 Performance validation of a novel Aspergillus Galactomannan kit H. Wang* (Beijing, China), C. Liu, J. Du, Y. Zhang, Y. Su 1080 An open-label study in healthy volunteers to evaluate the effect of fluconazole upon the pharmacokinetics of olorofim K. Cornelissen* (Manchester, United Kingdom), T. Kennedy, J.H. Rex, G. Allen, J. Steiner 1676 Risk factors and predictors of mortality of candidaemia among patients hospitalised in a Swiss university hospital M. Papadimitriou Olivgeris* (Lausanne, Switzerland), M. Papadimitriou-Olivgeris, F. Lamoth, L. Senn 195 Invasive aspergillosis in adult patients with rheumatic diseases N. Klimko* (Saint Petersburg, Russian Federation), V. Mazurov, A. Lila, O. Shadrivova, M. Tonkoshkur, M. Shostak, L. Martynova, O. Inamova, M. Petrova, A. Fonturenko, E. Desyatik, Y. Borzova, T. Bogomolova, S. Ignatyeva 1960 Multi-centre registry of patients receiving systemic mould-active triazoles for treatment or prophylaxis of invasive fungal infections L. Ostrosky-Zeichner* (Houston, United States), M.H. Nguyen, J. Bubalo, B.D. Alexander, M.H. Miceli, P. Pappas, J. Jiang, Y. Song, G.R. Thompson 1978 Antifungal consumption before and during the first wave of COVID-19: a French nationwide survey F. Lieutier-Colas* (Strasbourg, France), A. Jouzeau, A. Chabaud, C. Dumartin, M. Péfau, P. Berger, F. Botterel, A. Alanio, L. Hasseine, S. Ranque, A. Bacle, C. Rabaud, J.P. Gangneux, L. Simon 244 In vitro assay of zinc oxide nanoparticles efficiency in comparison with conventional antifungals against planktonic and biofilm- forming Candida albicans isolates from patients with cardiovascular disease O.S. Shalal* (Baghdad, Iraq), D. Alkurjiya 2469 (1 → 3)- β -D-glucan and mannan guided early termination of antifungal therapy in ICU patients: a prospective randomized intervention study (REDUCE-AM) J. Held* (Erlangen, Germany), T. Erb, S. Mihai, F. Cipa, L. Herbst, R. Strauß, I. Castellanos, A.K. Lang, M. Ganslmayer, C. Willam, A. Rath, K. Diesch 4048 The emergence of multidrug-resistant Candida duobushaemolnii: using whole genome sequencing to describe the population structure X.F. Chen* (Beijing, China), M. Xiao, X. Hou, Y.C. Xu 4211 Towards a program to optimise the use of antifungals in a universitary third level hospital P. Merino-Amador* (Madrid, Spain), F. González- Romo, R. Manzano, M. Magaz, A. Delgado- Iribarren 4390 Agreement of broncoalveolar lavage (BAL)- Aspergillus-PCR and BAL-galactomannan (GM): can BAL-GM overestimate the risk of probable COVID-19-associated pulmonary aspergillosis in ICU patients? S. Dettori* (Genoa, Italy), E. Furfaro, C. Russo, C. Dentone, D.R. Giacobbe, L. Magnasco, L. Taramasso, M. Mikulska, M. Bassetti 445 Aspergillus sensitisation in severe asthma patients N. Klimko* (Saint Petersburg, Russian Federation), Y. Kozlova, E. Frolova, A. Uchevatkina, L. Filippova, O. Aak, V. Kuznetsov, A. Sobolev, N. Vasilyeva 594 Treatment with isavuconazole (ISA) for invasive fungal infections (IFI) in solid organ transplant recipients (SOTR): real-life experience A. Monforte Pallares* (Barcelona, Spain) I. Los-Arcos, E. Márquez-Algaba, M.T. Martín- Gómez, D. Campany-Herrero, J. Sacanell, C. Berastegui, N. Nuvials, M. Deu, L. Castells, F. Moreso, C. Bravo, J. Gavaldà, O. Len All ePosters will be reviewed by the moderators. Friday, 9 July 2021Scientific Programme 35FINAL PROGRAMME – 31st ECCMID Online 2021 S61 09:30 - 10:30 7. Parasites & international health 1-hour ePoster Review Contemporary issues in the diagnosis of parasitic infections Moderators Zeno Bisoffi(Negrar di Valpolicella, Italy) Chileshe Mabula-Bwalya (Lusaka, Zambia) 104 Evaluation of nine commercial serological tests for the diagnosis of human hepatic cystic echinococcosis and the differential diagnosis with other focal liver lesions: a diagnostic accuracy study S.S. Longoni* (Verona, Italy), F. Tamarozzi, A. Vola, M. Degani, S. Tais, E. Rizzi, M. Prato, S. Scarso, R. Silva, E. Brunetti, Z. Bisoffi, F. Perandin 1235 Deep learning and microscopy: new perspectives in malaria diagnosis R. Grande* (Milan, Italy), C. Casati, D. Di Martino, M. Gismondo, R. Alberto 151 Evaluation of microscopy, serology, circulating anodic antigen, and eosinophil counts for the follow-up of migrants with chronic schistosomiasis: a prospective cohort study D. Buonfrate* (Negrar di Valpolicella, Italy), F. Tamarozzi, T. Ursini, P. Hoekstra, R. Silva, C. Costa, F. Gobbi, G. Monteiro, L. Motta, G. Van Dam, P. Corstjens, L. Van Lieshout 1687 Acanthamoebic keratitis: 5-year study from a tertiary care eye centre in India P. Rathod* (Delhi, India), N. Hussain Ahmed, J. Titiyal, R. Tandon, N. Sharma 1735 A web-based platform for training and quality control of parasite microscopy E. Tannich* (Hamburg, Germany), M. Benz, V. Bruns, M. Schillinger, C. Hammer, C. Kussin, V. Kaiser, N. Wojtalewicz, P. Schwarz, I. Schellenberg, U. Loderstädt, C. Wegner, B. Förster 1841 Evaluation of the Allplex TM Gastrointestinal Panel – Helminth(I) Assay for the detection of helminths and microsporidia in stool samples F. Robert-Gangneux* (Rennes, France), B. Autier, J.P. Gangneux 2101 A microbiological diagnosis of cutaneous leishmaniasis in real-time PCR era: a five-year experience in a referral centre in Barcelona A. Silgado* (Canovelles, Spain), M. Armas, A. Sánchez-Montalvá, L. Goterris, M. Ubals, J. Temprana-Savador, G. Aparicio, C. Chicharro, N. Serre-Delcor, B. Ferrer, I. Molina, V. Garcia- Patos, T. Pumarola, E. Sulleiro 222 Genotypic and phylogenetic analysis of cutaneous leishmaniasis in Al Ahsa (Eastern Saudi Arabia) during COVID-19 crisis: first case of Leishmania tropica with predominance of Leishmania major A. Al Rashed* (Al Khobar, Saudi Arabia), R. Al Jendan, S. Aljaroodi, A. Almuhanaa, A. Abdelhady, A. El-Badry 2515 Evaluation of eosinophilic cationic protein as a biomarker of alveolar and cystic echinococcosis H. Lagler* (Vienna, Austria), J. Hotz, P. Bauer, M. Kussmann, H. Auer 2692 Prevalence of Strongyloides infection among steroid recipients in a tertiary care centre in North India A. Ramprasad* (New Delhi, India), K. J, R. Bir, M. Soneja, P. Kodan, N. Verma, N. Wig, A. Biswas, B.R. Mirdha 2823 Validation of a multiplex real-time PCR gastrointestinal parasite panel M. Zhao* (Regina, Canada), K. Marks-Beaubrun, J. Kwan, R. Lau, A. Boggild 3125 Diagnostic performance and validation of a ready-to-use real-time PCR assay for the detection of Leishmania in human samples in comparison with three validated molecular methods A. Arnau* (Barcelona, Spain), C. Muñoz, M. Gàllego, A. Abras, C. Ballart, A. Fernández-Arévalo, T. Llovet, S. Tebar 3140 Clinical validation of a new real-time PCR molecular assay for the detection of Leishmania spp. in both cutaneous and visceral clinical samples C. Escolar* (Zaragoza, Spain), S. Migueláñez, J. Nieto, C. Chicharro-Gonzalo 3190 Screening versus single-pathogen detection when aiming for diagnosis of gastrointestinal infection caused by protist species A. Dashti* (Madrid, Spain), P.C. Köster, B. Bailo, D. Carmena 3243 Bioinformatically informed peptide microarray for the development of a specific and sensitive test for the diagnosis of hepatic cystic echinococcosis G. Batisti Biffignandi* (Pavia, Italy), F. Tamarozzi, A. Vola, M. Mariconti, E. Olivieri, L. Petrone, D. Sassera 4288 Validation of a qPCR for differential and quantitative characterisation of the five human Plasmodium, including P. knowlesi L. Barón Argos* (Madrid, Spain), C. Muñoz García, C. Carmona Rubio, J. Ligero López, M. Lanza Suarez, A. Jimenez Mejias, J.M. Rubio 4550 Validation of a multiplex real-time PCR gastrointestinal helminth panel K. Marks-Beaubrun* (North York, Canada), J. Kwan, R. Lau, F. Ralevski, A. Wang, R. Cudiamat, E. Chen, K. Orejana, A. Boggild 703 Screening of Echinococcus granulosus protoscolex antigens as novel candidates for the post-surgical follow-up of cystic echinococcosis in Tunisian paediatric patients E. Ben Salah* (Enfida, Tunisia), C. Barrera, W. Sakly, S. Mosbahi, A. Ksia, D. Makhlouf, B. Gottstein, A. Nouri, H. Babba, L. Millon Friday, 9 July 202136FINAL PROGRAMME – 31st ECCMID Online 2021 Friday, 9 July 2021 1473 Serological diagnosis of toxoplasmosis: evaluation of available commercial IgG immunoblot test based on recombinant antigens on 142 characterised human sera V. Jean-Pierre* (Grenoble, France), J. Miozzo, H. Fricker-Hidalgo, C. Garnaud, M.G. Robert, H. Pelloux, M.P. Brenier-Pinchart All ePosters will be reviewed by the moderators. S125 09:30 - 10:30 12. COVID-19 1-hour Mini Oral Flash COVID-19 across healthcare systems Chairs Dorothy Yeboah-Manu (Accra, Ghana) Dingding Zhang (Chengdu, China) 3119 09:30 Interventions to control nosocomial transmission of SARS-CoV-2: a modelling study T.M. Pham* (Utrecht, Netherlands), H. Tahir, J. Van De Wijgert, B. Van Der Roest, P. Ellerbroek, M. Bonten, M. Bootsma, M. Kretzschmar 1354 09:35 The impact of clinical biosafety training on the incidence of COVID-19 in healthcare workers A. Dmitrovskiy* (Almaty, Kazakhstan), M. Syzdykov, T. Yerubayev, A. Kuznetsov, T. Lyatomskaya, M. Kurmangazin, S. Maukayeva, G. Utepbergenova, K. Kamytbekova, T. Shishkina, N. Ospanbekova 3784 09:40 Effectiveness of non-contact infrared thermometers in identifying fever among healthcare workers during COVID-19 pandemic S. Dorairajan* (Chennai, India), S. Saravanakumar, S. Pooja, S. Kalyani 508 09:45 Other communicable diseases should not be neglected during the COVID-19 epidemic: data from the Campania region (Southern Italy) suggest a different approach F.M. Fusco* (Naples, Italy), R. Pisapia, A. D’argenzio, S. Esposito, A. De Gaetano, P. Arena, L. Porcaro, V. Morriale, G. Mazzarella 1566 09:50 Impact of two waves of the COVID-19 pandemic and of control measures implemented for hospitals in 2020 in France: lessons from the University Hospital of Clermont-Ferrand before the vaccination campaign and the emergence of new variants G. Laurichesse* (Clermont-Ferrand, France), M. Vidal, C. Dupuis, A. Mirand, J. Raconnat, J.E. Bazin, C. Henquell, O. Traoré, J. Schmidt, L. Cassagnes, S. Gomez, N. Mrozek, O. Lesens 3449 09:55 Factors associated with a delay in making an appointment to get tested for SARS-CoV-2 J. Bosdriesz* (Amsterdam, Netherlands), L. Dekkers, F. Ritsema, L. Coyer, A. Schreijer, Y. Van Duijnhoven, M. Schim Van Der Loeff, A. Matser ID 1238 10:00 The impact of air pollution on the severity of COVID-19 in Detroit, Michigan A. Shallal* (Detroit, United States), S. Joshi, D. Quan, L. Luna Wong, R. Kenney, M. Zervos 1239 10:05 Assessment of leading factors conditioning first wave cumulative COVID-19 mortality rate across 44 countries R.E. Quirós* (Caba, Bolivia), A. Vila, J. Farina 4189 10:10 Impact of the lockdown on the burden of SARS- CoV-2 infection in a French university hospital C. Elias* (Lyon, France), N. Khanafer, C. Dananché, L. Henaff, M. Saadatian-Elahi, P. Vanhems 10:15 Q&A/Discussion S110 10:45 - 12:15 1. Viral infections 1,5-hour Oral Session HIV infection: clinical considerations Chairs Milosz Parczewski (Szczecin, Poland) Juergen Rockstroh (Bonn, Germany) 582 10:45 Associations between plasma viral load and invasive cancer in people with HIV O. Elvstam* (Växjö, Sweden), G. Marrone, P. Medstrand, C.J. Treutiger, V. Svedhem, M. Gisslén, P. Björkman 1490 10:55 No risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection switching protease inhibitor-based therapy R. Lajaunie* (Toulouse, France), L. Cuzin, R. Palich, A. Makinson, F. Bani-Sadr, C. Duvivier, C. Arvieux, D. Rey, I. Poizot-Martin, C. Delpierre, P. Delobel, G. Martin-Blondel 3561 11:05 Suppressive combination antiretroviral therapy in people infected with HIV-1 is associated with a decrease of the reactive dicarbonyl methylglyoxal. S.H. Lowe* (Maastricht, Netherlands), S. Kuijk Van, R. Ackens, C. Schalkwijk 339 11:15 Dolutegravir/rilpivirine in supressed HIV- infected persons between 2015 and 2020 A. Díaz-De Santiago* (Madrid, Spain), S. De La Fuente, A. Gutierrez, R. Cuadrillero, C. Folguera 4501 11:25 Liver transplantation among HIV-infected patients: experience with 37 patients from a reference centre in Lisbon, Portugal E. Ferreira Leal* (Lisbon, Portugal), A. Dias, D. Póvoas, M. Leal, A. Caeiro, H. Pinheiro, M. Torres, C. Cruz, R. Pinto, A.R. Garrote, S. Lino, J. Ramirez, D. Seixas, S. Betkova, O. Cardoso, J. Ribeiro, M.J. Manata, A. Martins, F. Maltez IDScientific Programme 37FINAL PROGRAMME – 31st ECCMID Online 2021 Friday, 9 July 2021 4243 11:35 U=U: Undetectable = Untransmittable knowledge of the evidence and stigma against people who live with HIV in health school students D. Paganini* (Pisa, Italy), S. Mazzilli, V. Casigliani, A. Baggiani, L. Tavoschi 11:45 Q&A/Discussion 2229 10:45 - 12:15 2. Bacterial infection 1,5-hour Educational Workshop Prevention of endocarditis Chairs Nuria Fernàndez-Hidalgo (Barcelona, Spain) Jacob Strahilevitz (Jerusalem, Israel) 2229-1 10:45 Antibiotic prophylaxis of endocarditis for dental procedures: where are we beyond 2020? Catherine Leport (Paris, France) 2229-2 11:05 Non-antibiotic chemoprophylaxis of endocarditis: an update Philippe Moreillon (Lausanne, Switzerland) 2229-3 11:25 Opportunities and failures in secondary prevention of endocarditis José M. Miro (Barcelona, Spain) 11:45 Q&A/Discussion Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES) S53 10:45 - 11:45 4. Diagnostics 1-hour Mini Oral Flash Machine learning, artificial intelligence and novel applications in diagnostic microbiology Chairs Amel Renaud Bidias (Lambarene, Gabon) Anja Šterbenc (Ljubljana, Slovenia) 1053 10:45 Performance of Fourier-transform infrared spectroscopy typing: a monocentric study using a prospective two-year collection of 284 clinical extended-spectrum β -lactamase-producing Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae complex isolates from three clinical wards with high risk of outbreaks F. Gravey* (Caen, France), M. Cordovana, M. Auzou, M. Fines-Guyon, D. Du Cheyron, F. Ethuin, L. Fazilleau, C. Jeanne-Leroyer, S. Hecht, L. Gebauer, M. Kostrzewa, S. Le Hello, O. Join-Lambert 1796 10:50 Clinical validation of machine learning-based approach in multiplex digital PCR for accurate detection of carbapenem-resistance genes L. Miglietta* (London, United Kingdom), A. Moniri, F. Bolt, F. Davies, A. Holmes, P. Georgiou, J. Rodriguez-Manzano ID CM 1980 10:55 Rapid non-destructive and automated bacterial identification by image-based diffraction pattern analysis J. Peyroux* (La Tronche, France), Y. Caspar, A. Lbath, M. Maurin 2010 11:00 Validation of APAS independence (CCS) artificial intelligence (AI) algorithms to detect MRSA in a routine setup S. Krienke* (Cologne, Germany), A. Nowag, H. Wisplinghoff, S. Giglio, S. Wirth, N. Jazmati 2022 11:05 Usefulness of a new acid-fast bacilli detection method based on image analysis (virtual slide) M. Mitsuru* (Tokyo, Japan), K. Horiuchi, S. Ishigaki, Y. Ono 3039 11:10 Nondestructive optical identification of pathogens on agar through laser backscattering P.R. Marcoux* (Grenoble, France), M. Fourar, H. Hamerlinck, E. Naessens, F. Ngolè, S. Benahmed, E. Bergmann, D. Decq, X. Mermet, C. Belafdil, O. Gal, P. Grohs, B. Verhasselt, M. Roch, E. Schultz 3590 11:15 Artificial intelligence and large field, high- resolution lensless imaging for non- destructive, label-free identification directly on agar P. Schiavone* (Grenoble, France), I. Zamoun, S. Soulan, A. Maire, M. Gougis, P.R. Marcoux, T. Yescas González, G. Mugnier, E. Picard, M. Zelsmann, E. Hadji, D. Peyrade 3943 11:20 CRISPR as a new typing tool for Streptococcus agalactiae invasive strains A. Pastuszka* (Tours, France), N. Lepine, C. Lemaire, B. Le Gallou, L. Mereghetti, P. Lanotte 435 11:25 Validation of FTIR spectroscopy for high- throughput serotyping of Streptococcus pneumoniae P.J. Ceyssens* (Brussels, Belgium), I. Passaris, N. Mauder, M. Kostrzewa, H.C. Slotved, N.M. Van Sorge, S. Desmet 516 11:30 Interpretive medical knowledge engines: a new service for pathologists to bridge the gap to clinicians K.P. Adlassnig* (Vienna, Austria), J. Gawrylkowicz, A. Rappelsberger 11:35 Q&A/Discussion 38FINAL PROGRAMME – 31st ECCMID Online 2021 Friday, 9 July 2021 S48 10:45 - 12:15 5. Antimicrobials & stewardship 1,5-hour Oral Session Multidisciplinary science underpins antimicrobial stewardship Chairs Namita Jaggi (Gurgaon, India) Minggui Wang (Shanghai, China) 4162 10:45 Long-term follow-up of a multidisciplinary antibiotic stewardship intervention in a high- endemic setting for multidrug-resistant pathogens M. Sibani* (Verona, Italy), E. Carrara, L. Barbato, F. Mazzaferri, N.D. Salerno, A. Dalbeni, P. Minuz, O. Olivieri, L. Bissoli, V. Di Francesco, T. Evelina 4099 10:55 Practice testing of generic quality indicators for responsible antibiotic use in 9 hospitals in the Dutch-Belgian border area A. Monnier* (Nijmegen, Netherlands), V. D’onofrio, I. Willemsen, M. Kluytmans, J. Kluytmans, A. Schuermans, I. Leroux-Roels, I.C. Gyssens 3436 11:05 A mixed methods, theory-driven investigation of the social and behavioural drivers of antimicrobial prescribing in an Irish acute teaching hospital G. Hughes* (Dublin, Ireland), A.F. Talento, A. O’ Leary, C. Bergin 2634 11:15 Assessment of patients’ perceptions and attitudes toward antibiotic use and their role in antimicrobial stewardship within the movement to reduce antimicrobial resistance W.J. Moore* (Chicago, United States), S. Wang, S. Sutton, M. Porter 1748 11:25 Physicians’ knowledge, attitudes and practices regarding antibiotic prescribing and stewardship in Indonesian hospitals R. Limato* (Jakarta, Indonesia), E.J. Nelwan, M. Alamanda, M. Mudia, E.R. Manurung, I.Y. Mauleti, M. Mayasari, I. Firmansyah, R. Djafaar, R.L. Hamers 2362 11:35 Bedside nurse’s role in antimicrobial stewardship activities: a conscious contribution? M. Bos* (Nijmegen, Netherlands), J. Schouten, C. De Bot, H. Vermeulen, M. Hulscher 2491 11:45 Monitoring of quality indicators for antibiotic use in Belgian hospitals: are we improving? A. Versporten* (Antwerp, Belgium), E. Vandael, K. Latour, I. Pauwels, K. Magerman, B. Catry, H. Goossens 11:55 Q&A/Discussion ID S81 10:45 - 12:15 7. Parasites & international health 1,5-hour Case Session Parasites full of surprises Chairs Nick Beeching (Liverpool, United Kingdom) Daniel Grupel (Be'er Sheva, Israel) 1721 10:45 Extraintestinal enterobiasis presenting as adnexal tumour in postmenopausal woman J. Racková* (Prague, Czech Republic) 1993 10:55 Hookworm infection presenting as recurrent severe anaemia requiring blood transfusion in a Pakistani migrant to Italy L. Zammarchi* (Florence, Italy), G. Barbarisi, M. Piccica, M. Zavagli, G. Bandini, N. Di Lauria, A. Antonelli, M. Spinicci, G.M. Rossolini, A. Bartoloni, A. Moggi Pignone 3390 11:05 Successful outcome of disseminated cerebral amoebiasis in a non-traveling Spanish host A.C. Gallotti* (Madrid, Spain), P. Sanchez, F.J. Merino, J. Ligero, K.M. Pinto Tapia, O.M. Muñoz Clemente 4052 11:15 How many more deaths will be needed? Post- mortem diagnosis of imported malaria in France: a case report J. Sevestre* (Nice, France), C. Bernardi, M. Gillet, P. Delaunay, Y. Fanjat, G. Toni, P. Marty, V. Alunni, C. Pomares 3098 11:25 Delayed haemolysis after IV artesunate therapy for Plasmodium falciparum infection: first report in Republic of Ireland R. O’ Connor* (Dublin, Ireland), C. Grant, C. Bannan, C. Conlan, N. Kinsella, C. Merry, B. Carr, G. Melanophy, C. Bergin 1421 11:35 Clinical spectrum and management approach of complicated imported urogenital schistosomiasis: a multi-centre TropNet study G. Basile* (Florence, Italy), F. Tamarozzi, L. Moro, S. Antinori, M. Arsuaga, J. Salas Coronas, M.T. Giordani, A. Bartoloni, L.R. Tomasoni, F.G. Gobbi, L. Zammarchi 2456 11:55 Breast schistosomiasis involving Schistosoma haematobium: a case report M.G. Robert* (Grenoble, France), O. Palaprat, E. Nika, A. Delouche, F. Quenard, M. Chevalier, D. Maubon, H. Pelloux 12:05 Q&A/Discussion IDScientific Programme 39FINAL PROGRAMME – 31st ECCMID Online 2021 Friday, 9 July 2021 2343 10:45 - 12:15 8. Infection prevention & control 1,5-hour Educational Workshop How to implement effective antimicrobial stewardship linked to infection prevention Chairs Nico Mutters (Bonn, Germany) Anders F Johansson (Umea, Sweden) 2343-1 10:45 Novel strategies to influence antibiotic prescribing behaviour and infection prevention practice Esmita Charani (London, United Kingdom) 2343-2 11:05 Linking prescribing to prevention: a practical approach Evelina Tacconelli (Verona, Italy) 2343-3 11:25 Global implementation of infection control and stewardship programmes: the WHO perspective Benedetta Allegranzi (Geneva, Switzerland) 2343-5 11:45 Q&A/Discussion Co-organised with: European Committee on Infection Control (EUCIC) and World Health Organization (WHO) 2479 10:45 - 12:15 9. Basic microbiology 1,5-hour Symposium Looking deeper into the microbiota Chairs Leo Lahti (Turku, Finland) Willem Van Schaik (Birmingham, United Kingdom) 2479-1 10:45 Microbial interactions in bacterial vaginosis Nuno Cerca (Braga, Portugal) 2479-2 11:05 Delivery mode impacts newborn gut colonisation efficiency Moran Yassour (Jerusalem, Israel) 2479-3 11:25 Gut microbiome and host immunity Elizabeth Mann (Manchester, United Kingdom) 2479-4 11:45 Role of bacteriocins and bacteriophage in shaping the composition of the human microbiome Paul Ross (Cork, Ireland) 12:05 Q&A/Discussion Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI) 2685 10:45 - 11:45 11. Special sessions & Other 1-hour Symposium Year in Infectious Diseases Chairs Cristina Mussini (Modena, Italy) Pierre Tattevin (Rennes, France) 2685-1 10:45 Graeme Ayton Meintjes (Cape Town, South Africa) 2685-2 11:05 Chiara Iaria (Palermo, Italy) 11:25 Q&A/Discussion IC CM ID S91 10:45 - 12:15 12. COVID-19 1,5-hour Oral Session COVID-19 in high risk patient populations Chairs Matteo Bassetti (Genoa, Italy) Margaret Ip (Hong Kong, Hong Kong) 2457 10:45 Clinical outcomes in patients hospitalised with HIV and COVID-19; a Romanian multi-centre study C. Oprea* (Bucharest, Romania), I. Ianache, R. Cernat, M. Arbune, E.V. Lazureanu, F. Dumitrescu, M. Ispas, S. Piscu, A. Georgescu 3844 10:55 Clinical outcome of solid organ transplant patients with COVID-19: a multi-centre study from Argentina P. Giorgio* (Buenos Aires, Argentina), N. Pujato, E. Temporiti, M. Martinez, C. Nagel, C. Salgueira, R. Gago, M. Ajzenszlos, R. Grosso, L. Barcan 3687 11:05 SARS-CoV-2 prolonged viral replication in haematological patients P. Puerta-Alcalde* (Barcelona, Spain), C. Jordán- Iborra, G. Cuesta-Chasco, N. García-Pouton, M. Chumbita, F. Meira, G. Dueñas, G. Julia, A. Cózar-Llistó, S. Marta, C. Lopera, A. Gaya, E. Giné, L. Magnano, J. Mensa, F. Fernández- Avilés, J. Esteve, M.Á. Marcos, A. Soriano, C. Garcia-Vidal 3986 11:15 SARS-CoV-2 impact in cancer patients in the Principality of Andorra (COVONCO study) C. Royo-Cebrecos* (Escaldes-Engordany, Andorra), I. Ambatlle, Ï. Robert-Montaner, J.M. Buldon, D. Vilanova, E. Bailles, E. Mahia, J. Pujadas, F. Cobo, S. Albiol 2789 11:25 Clinical epidemiology and risk factors for severe diseases of elderly COVID-19 hospitalised patients in Japan H. Nomoto* (Tokyo, Japan), A. Yusuke, H. Kayoko, M. Nobuaki, T. Shinya, T. Mari, O. Hiroshi, K. Koji, S. Kumiko, S. Tetsuya, N. Keiji, M. Shinichiro, S. Sho, S. Fumitake, O. Norio 2497 11:35 Clinical presentation, investigations and outcomes of pregnant women with COVID-19 in a maternity centre with a high Black, Asian and minority ethnic population: a retrospective cohort study B. Canning* (Birmingham, United Kingdom), N. Eltaweel, E.E. Tan, M. Kidd, P. Surana, S. Patni, S.F. Atabani 2248 11:45 Clinical manifestations, disease severity and outcomes in pregnant women with SARS-CoV-2 infection E. Zappulo* (Naples, Italy), A. Gallicchio, A.R. Buonomo, M. Foggia, L. Cattaneo, S. Mercinelli, N. Schiano Moriello, G. Viceconte, M. Locci, G. Bifulco, I. Gentile 11:55 Q&A/Discussion PHNext >